DB05469ExperimentalSmall molecule
R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence. Phase IIa data for... Phase IIa data for the drug show it reduced the number of incontinent episodes compared to placebo with minimal cardiovascular effects.
- Mechanism
- Curator reviewed
R450 is a selective alpha 1 adrenoreceptor antagonist. Research on the management of urinary incontinence suggests that it is most likely an antagonist at alpha-1B and alpha-1D, while it acts as an agonist on alpha-1a.
- Primary indication
- Investigated for use/treatment in urinary incontinence.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with R450, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account